Elizabeth Smyth

19.6k total citations · 9 hit papers
142 papers, 9.8k citations indexed

About

Elizabeth Smyth is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Elizabeth Smyth has authored 142 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pulmonary and Respiratory Medicine, 80 papers in Surgery and 77 papers in Oncology. Recurrent topics in Elizabeth Smyth's work include Gastric Cancer Management and Outcomes (89 papers), Esophageal Cancer Research and Treatment (59 papers) and Colorectal Cancer Treatments and Studies (27 papers). Elizabeth Smyth is often cited by papers focused on Gastric Cancer Management and Outcomes (89 papers), Esophageal Cancer Research and Treatment (59 papers) and Colorectal Cancer Treatments and Studies (27 papers). Elizabeth Smyth collaborates with scholars based in United Kingdom, United States and Italy. Elizabeth Smyth's co-authors include Florian Lordick, David Cunningham, Nicole C.T. van Grieken, Magnus Nilsson, Heike I. Grabsch, Jesper Lagergren, Pernilla Lagergren, William Allum, Andrés Cervantes and Marcel Verheij and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Elizabeth Smyth

130 papers receiving 9.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gastric cancer

2020 3.0k citations Elizabeth Smyth, Magnus Nilsson et al. The Lancet profile →
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 1.1k citations Elizabeth Smyth, William Allum et al. Annals of Oncology profile →
Oesophageal cancer

2017 831 citations Jesper Lagergren, Elizabeth Smyth et al. The Lancet profile →
Oesophageal cancer

2017 691 citations Elizabeth Smyth, Jesper Lagergren et al. profile →
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 646 citations Florian Lordick, Elizabeth Smyth et al. Annals of Oncology profile →
Mismatch Repair Deficiency, Microsatellite Instability, and Survival

2017 365 citations Elizabeth Smyth, Andrew Wotherspoon et al. profile →
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 293 citations Florian Lordick, Magnus Nilsson et al. Annals of Oncology profile →
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

2023 124 citations Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology profile →
Gastric cancer

2025 17 citations Raghav Sundar, Kohei Shitara et al. The Lancet profile →

Peers

Countries citing papers authored by Elizabeth Smyth

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Smyth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Smyth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Smyth more than expected).

Fields of papers citing papers by Elizabeth Smyth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Smyth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Smyth. The network helps show where Elizabeth Smyth may publish in the future.

Co-authorship network of co-authors of Elizabeth Smyth

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Smyth. A scholar is included among the top collaborators of Elizabeth Smyth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Smyth. Elizabeth Smyth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol 2024 ·SHILAP Revista de lepidopterología ·Angelica Petrillo, Lindsey Oudijk, Raghav Sundar, (unknown), (unknown), (unknown), Murielle Mauer, Nicole C.T. van Grieken, Elizabeth Smyth, Markus Moehler	2
2	495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC) 2024 ·Annals of Oncology ·(unknown), Yelena Y. Janjigian, Elena Elimova, (unknown), M-H. Chen, Elizabeth Smyth, Joyce Lee, (unknown), (unknown), (unknown), (unknown)	3
3	CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Alexander G. Raufi, Lipika Goyal, Elizabeth Smyth, Philip Szekeres, Marcella Petrone, (unknown), Kenneth S. Thress, (unknown), (unknown), (unknown), Rakesh Kumar, (unknown), Laura Barker, Yelena Y. Janjigian, Kohei Shitara	3
4	499TiP A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive: DECIPHER (TRIALS IN PROGRESS) 2024 ·Annals of Oncology ·Elizabeth Smyth, Daniel E. Griffiths, Kelly Cozens, Chris Hurt, Robert Waugh, Richard Turkington, Kieran Foley, (unknown), (unknown), (unknown), (unknown), (unknown), Richard Owen, (unknown), Catherine Steel, Gareth Griffiths	0
5	Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE 2024 ·ESMO Open ·(unknown), Susanna Slater, Claire Saffery, (unknown), (unknown), Gillian Smith, Maria Aresu, Darina Kohoutová, (unknown), (unknown), Isma Rana, Edward W. Johnston, (unknown), Elizabeth Smyth, Wasat Mansoor, (unknown), Shuan Rao, Ian Chau, Naureen Starling, David Cunningham	4
6	Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscape 2024 ·SHILAP Revista de lepidopterología ·Chiara Alessandra Cella, Davide Ciardiello, Lorenzo Gervaso, Hanneke W.M. van Laarhoven, Luigi Nezi, Carlotta Catozzi, Florian Lordick, Elizabeth Smyth, Stefano De Pascale, (unknown), Carmine Valenza, (unknown), Uberto Fumagalli Romario, Nicola Fazio	3
7	1428P Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study 2024 ·Annals of Oncology ·(unknown), (unknown), Jung Wook Yang, Augustinas Baušys, Lorenzo Ferri, Geoffrey Y. Ku, Elizabeth Smyth, (unknown), (unknown)	1
8	Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study breakdown → 2023 ·The Lancet Oncology ·Eric Van Cutsem, Maria Di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer A. Ajani, Joseph Chao, Yelena Y. Janjigian, Amy Qin, Jasmeet Singh, Ferdous M. Barlaskar, Yoshinori Kawaguchi, Geoffrey Y. Ku	124
9	SO-12 CLDN18.2 expression in resectable gastroesophageal cancers: Associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity 2023 ·Annals of Oncology ·(unknown), Ginny Devonshire, Ahmad Miremadi, Liang Zhuang, (unknown), Rona Smith, (unknown), (unknown), Lorenza Rimassa, Rebecca C. Fitzgerald, Elizabeth Smyth	1
10	Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma 2021 ·Journal of Clinical Oncology ·Joseph J. Zhao, Dominic Wei Ting Yap, Yiong Huak Chan, Benjamin Kye Jyn Tan, Chong Boon Teo, Nicholas Syn, Elizabeth Smyth, Yu Yang Soon, Raghav Sundar	112
11	Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature 2021 ·Cancer Treatment Reviews ·Christelle de la Fouchardière, Lore Decoster, Emmanuelle Samalin, C. Terret, Cindy Kenis, Jean‐Pierre Droz, Clélia Coutzac, Elizabeth Smyth	5
12	The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma 2021 ·Journal of Surgical Oncology ·(unknown), (unknown), Wahyu Wulaningsih, D Foley, Dionysios Dellaportas, Janine Zylstra, Cara Baker, Mark Kelly, Elizabeth Smyth, Jesper Lagergren, Nick Maisey, William Allum, James Gossage, David Cunningham, Andrew Davies	1
13	Progress and challenges in gastroesophageal cancer 2020 ·Current Problems in Cancer ·(unknown), Elizabeth Smyth, Florian Lordick	5
14	Gastric cancer breakdown → 2020 ·The Lancet ·Elizabeth Smyth, Magnus Nilsson, Heike I. Grabsch, Nicole C.T. van Grieken, Florian Lordick	3025
15	Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future 2018 ·Annals of Oncology ·(unknown), David Cunningham, Florian Lordick, Elizabeth Smyth	14
16	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy 2017 ·Clinical Cancer Research ·Elizabeth Smyth, Shenli Zhang, David Cunningham, Andrew Wotherspoon, Richie Soong, Clare Peckitt, Nicola Valeri, Matteo Fassan, Massimo Rugge, Alicia Okines, William Allum, Sally Stenning, Matthew Nankivell, Ruth E. Langley, Patrick Tan	9
17	Rash, neutrophil-lymphocyte ratio (NLR) and survival in the REAL3 trial 2017 ·Annals of Oncology ·Elizabeth Smyth, Kyriakos Kouvelakis, Clare Peckitt, Thomas K. Waddell, Daniel W. Watkins, (unknown), Naureen Starling, Claire Saffery, Alicia Okines, Ian Chau, David Cunningham	1
18	MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell lines 2016 ·Annals of Oncology ·Hazel Lote, Domenico Zito, Rosemary Burke, Elizabeth Smyth, Chiara Braconi, David Cunningham, Nicola Valeri	1
19	Targeted Therapy for Gastric Cancer 2012 ·Current Treatment Options in Oncology ·Elizabeth Smyth, David Cunningham	59
20	Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma 2011 ·Clinical Cancer Research ·Mrinali Patel, Elizabeth Smyth, Paul B. Chapman, Jedd D. Wolchok, Gary K. Schwartz, David H. Abramson, Richard D. Carvajal	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact